Stealth BioTherapeutics Inc. (MITO) stock rose during after-hours, provided no current update.

Stealth BioTherapeutics Inc. (NASDAQ: MITO) stock plunged by 3.57% at last close whereas the MITO stock price gains by 6.17% in the after-hour trading session.  Stealth BioTherapeutics is a clinical-stage biotechnology firm dedicated to the research, development, and marketing of innovative medicines for mitochondrial illnesses. Mitochondria are the body’s principal source of energy generation and are essential for appropriate organ function.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

MITO stock’ Recent Development

On Dec 20, 2021 Stealth BioTherapeutics provided information on its Duchenne muscular dystrophy (DMD) research programme following a pre-IND meeting with the FDA’s Division of Cardiology and Nephrology (DCN). It also entails reaching agreement on Stealth’s proposal to use myocardial fibrosis progression as a surrogate endpoint in a clinical study.

The pre-investigational new drug (IND) meeting was held to examine Stealth’s projected DMD development strategy. DCN agreed that cardiac fibrosis measured with late gadolinium enhancement (LGE) on magnetic resonance imaging (MRI) may be used as a main endpoint in Stealth’s planned new clinical study. DCN also described the processes that would be required for an Accelerated Approval based on this outcome if it is determined that slowing fibrosis progression is reasonably expected to result in therapeutic benefit in DMD.

DCN said that the clinical study design was in line with various critical features, while urging that further information be presented with Stealth’s anticipated IND on others. Stealth intends to meet with DCN again early next year as it progresses toward submitting an IND in the first part of the year and perhaps starting a study in the second half of the year, depending on regulatory comments and funding.

Furthermore,

New preclinical evidence from Stealth has shown that combining elamipretide with an exon-skipping phosphorodiamidate morpholino oligomer (PMO) dramatically enhances dystrophin expression levels in the X-linked muscular dystrophy (mdx) mouse model. PMO is a medicinal class that has previously been approved by the FDA and commercialised for its effects on skeletal muscle.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular